Detalhe da pesquisa
1.
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
J Am Acad Dermatol
; 89(6): 1149-1158, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37553030
2.
Estradiol suppresses psoriatic inflammation in mice by regulating neutrophil and macrophage functions.
J Allergy Clin Immunol
; 150(4): 909-919.e8, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35589416
3.
Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges.
Int J Mol Sci
; 23(15)2022 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35955666
4.
Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?
Int J Mol Sci
; 23(20)2022 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36293117
5.
Diversified Stimuli-Induced Inflammatory Pathways Cause Skin Pigmentation.
Int J Mol Sci
; 22(8)2021 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33921371
6.
Inflammatory Molecules Associated with Ultraviolet Radiation-Mediated Skin Aging.
Int J Mol Sci
; 22(8)2021 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33921444
7.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Lancet
; 392(10148): 650-661, 2018 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30097359
8.
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
N Engl J Med
; 375(4): 345-56, 2016 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27299809
9.
Risk Factors for the Development of Psoriasis.
Int J Mol Sci
; 20(18)2019 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31491865
10.
Exploring patient background and biomarkers associated with the development of dupilumab-associated conjunctivitis and blepharitis.
Allergol Int
; 73(2): 332-334, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38151410
11.
Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B-PAD study).
Clin Exp Allergy
; 53(2): 233-238, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36524532
12.
Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials.
J Drugs Dermatol
; 17(2): 200-206, 2018 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29462229
13.
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
J Am Acad Dermatol
; 76(3): 441-448.e2, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28027825
14.
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
J Am Acad Dermatol
; 76(3): 432-440.e17, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27889292
15.
Role of Class III phosphoinositide 3-kinase in the brain development: possible involvement in specific learning disorders.
J Neurochem
; 139(2): 245-255, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27607605
16.
Transgenic rat model of childhood-onset dermatitis by overexpressing telomerase reverse transcriptase (TERT).
Transgenic Res
; 25(4): 413-24, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26885830
17.
Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis.
Int J Mol Sci
; 17(6)2016 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27271600
18.
CCL27 is downregulated by interferon gamma via epidermal growth factor receptor in normal human epidermal keratinocytes.
J Cell Physiol
; 229(12): 1935-45, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24710735
19.
Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post-marketing surveillance study.
J Dermatol
; 2024 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38775204
20.
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.
J Dermatol
; 51(3): 365-379, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268101